Caplin Point Laboratories Ltd.

NSE: CAPLIPOINT · Healthcare

₹2,382.50-1.61%06 Nov 2026

Ask the data

Instant answers about Caplin Point Laboratories Ltd. — computed from its filings, no language model

Market cap₹18,107 cr

Current price₹2,382.50

High / Low₹2,867 / ₹1,505

P/E27.2

P/B5.05

Book value₹471.9

ROE18.6%

ROCE23.5%

Debt / equity0.00

Dividend yield0.25%

EPS (TTM)₹87.55

Face value₹2

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 8 periods

	FY18	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	540	863	1,061	1,269	1,467	1,694	1,937	2,187
EBITDA	195	260	329	395	441	551	647	761
Operating margin	36.1%	30.1%	31.0%	31.1%	30.1%	32.6%	33.4%	34.8%
Interest	0	0	2	1	1	1	1	1
Depreciation	19	32	37	47	45	53	66	73
Profit before tax	188	269	314	386	451	564	677	803
Tax	44	54	62	77	74	103	136	153
Net profit	145	215	242	308	376	457	563	641
EPS ₹	19.26	28.42	32.03	39.61	49.62	60.19	70.57	84.36
Operating cash flow	—	—	—	337	272	311	432	523
Capex	—	—	—	91	194	146	192	248
Dividend paid	—	—	—	23	30	34	38	46
Total assets	500	1,126	1,364	1,736	2,191	2,697	3,209	4,045
Equity	364	948	1,186	1,484	1,880	2,316	2,850	3,586

Quarterly performance

last 31 quarters · ₹ crore

showing latest 8 of 31 periods

	MAR '18	SEP '18	DEC '18	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
Revenue	143	156	159	227	228	215	2	268	274	279	300	304	326	339	346	359	372	389	395	410	436	453	459	483	493	502	510	534	543	600	610
Operating profit	49	56	58	71	68	54	1	87	84	86	93	101	101	100	102	106	109	124	127	137	142	145	152	165	162	168	178	189	190	204	213
Operating margin	34.0%	35.8%	36.3%	31.3%	29.7%	25.0%	30.0%	32.6%	30.6%	30.7%	30.8%	33.3%	31.0%	29.5%	29.5%	29.4%	29.4%	31.8%	32.0%	33.5%	32.7%	32.0%	33.1%	34.1%	32.9%	33.4%	34.8%	35.4%	34.9%	34.0%	35.0%
Other income	3	7	8	7	10	20	0	2	6	9	9	8	10	12	14	16	14	11	12	20	17	17	19	21	31	26	23	30	34	28	34
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	6	6	6	7	8	8	0	9	9	10	12	12	12	11	11	11	11	11	11	12	14	16	16	17	16	17	16	18	19	19	22
Profit before tax	45	57	60	71	70	65	1	80	80	85	90	98	99	100	105	110	112	124	127	146	145	146	154	169	177	177	184	201	204	213	225
Tax	10	14	14	13	11	16	0	17	14	17	18	21	19	19	19	18	14	23	23	30	26	25	29	38	37	31	34	41	38	41	46
Net profit	35	47	46	57	59	49	1	57	64	66	71	77	75	81	85	92	97	102	103	115	117	122	124	131	139	141	153	154	164	170	177
EPS ₹	4.76	6.21	6.06	7.58	7.74	6.46	7.21	7.52	8.52	8.78	9.37	9.91	9.90	10.43	11.21	12.09	12.86	13.45	13.62	15.13	15.44	16.01	16.32	17.22	18.28	18.75	20.10	20.32	21.56	22.38	23.27
Revenue YoY	—	—	—	45.8%	43.5%	—	—	18.0%	20.2%	29.5%	12418.3%	13.2%	18.9%	21.7%	15.3%	18.3%	14.1%	14.8%	14.1%	14.2%	17.0%	16.4%	16.1%	17.8%	13.2%	10.9%	11.2%	10.5%	10.1%	19.4%	19.6%
Profit YoY	—	—	—	22.3%	28.0%	—	—	-0.8%	9.9%	35.8%	12781.8%	35.0%	16.3%	21.8%	20.0%	19.3%	30.1%	26.3%	21.7%	25.3%	20.2%	19.1%	19.9%	13.9%	18.6%	15.8%	23.3%	18.1%	17.9%	20.8%	15.8%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Caplin Point Laboratories Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 9 periods

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	58	62	69	103	122	158	219	299	348
Operating profit	1	2	8	9	21	28	47	81	101
Operating margin	2.1%	2.7%	11.1%	8.8%	17.2%	17.7%	21.6%	27.0%	29.0%
Other income	2	4	2	2	2	3	3	4	6
Interest	1	1	1	1	0	0	0	0	—
Depreciation	1	1	1	1	1	2	7	10	13
Profit before tax	1	4	7	9	21	29	43	75	93
Tax	0	1	2	3	6	8	8	17	23
Net profit	1	3	6	7	16	20	35	58	71

Quarters

showing latest 8 of 42 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	12	9	12	14	16	15	13	15	14	13	20	13	20	16	20	28	21	27	26	33	30	29	29	36	40	41	41	46	54	57	61	68	75	77	79	80	83	89	96	102	115	111
Operating profit	0	-1	-0	-1	1	1	-0	-1	-0	1	2	1	3	2	3	2	2	2	3	3	7	5	5	4	5	9	10	9	11	12	14	18	21	22	20	20	22	25	33	34	47	37
Operating margin	0.9%	-8.3%	-0.2%	-5.1%	8.8%	4.9%	-1.6%	-7.6%	-1.7%	5.5%	11.6%	3.8%	14.3%	9.8%	13.7%	6.1%	7.2%	9.2%	12.5%	9.2%	23.2%	18.5%	18.5%	10.3%	12.7%	22.9%	24.0%	20.0%	20.8%	21.4%	23.5%	27.4%	27.2%	28.6%	25.0%	25.6%	26.6%	28.0%	34.7%	33.3%	41.3%	33.4%
Other income	1	1	0	0	0	1	1	2	1	0	0	1	0	0	0	0	1	1	1	1	1	0	0	0	0	1	1	1	1	1	1	1	1	1	2	1	2	1	2	4	3	2
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	—	0	0	0
Depreciation	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	2	2	1	3	2	3	3	3	3	3	5	4	4	5
Profit before tax	0	-1	-0	-1	1	1	0	1	0	1	2	1	3	1	3	2	2	3	3	3	7	6	5	3	5	10	10	8	10	11	14	16	19	21	19	19	21	23	30	34	46	35
Tax	0	0	-0	0	0	0	0	1	0	0	-0	0	1	0	0	0	0	1	1	0	2	2	2	2	1	2	4	1	1	2	3	3	5	5	3	5	4	6	8	10	13	11
Net profit	0	-1	-0	-1	1	0	0	0	0	1	2	0	2	1	2	1	1	2	2	3	5	4	4	2	4	8	7	7	9	9	11	13	14	16	15	14	17	18	22	24	33	24
EPS ₹	0.09	-0.61	—	-1.01	1.02	0.33	0.04	0.18	0.09	0.34	1.52	0.25	1.26	0.61	1.65	0.78	0.81	1.35	1.38	1.88	3.62	2.37	2.43	1.05	2.51	5.33	4.54	4.58	5.64	6.03	7.01	8.40	9.40	10.57	10.03	9.54	11.14	2.34	2.90	3.23	4.34	3.13
Revenue YoY	—	—	—	—	33.4%	68.8%	13.6%	8.4%	-14.3%	-9.6%	51.1%	-10.2%	45.3%	18.1%	2.3%	107.9%	8.5%	72.3%	28.4%	17.6%	40.9%	8.0%	10.9%	8.9%	32.0%	39.3%	42.2%	27.8%	36.8%	40.7%	47.2%	47.1%	38.8%	34.3%	29.1%	17.8%	9.4%	15.7%	22.4%	28.1%	38.9%	24.1%
Profit YoY	—	—	—	—	1100.0%	—	—	—	-89.4%	6.1%	4500.0%	35.7%	1264.3%	76.9%	8.7%	207.9%	-35.6%	121.7%	-16.8%	141.9%	344.7%	75.5%	76.4%	-43.8%	-30.7%	124.9%	87.2%	335.8%	125.1%	13.2%	54.3%	83.3%	66.5%	75.4%	42.9%	13.5%	18.5%	10.8%	44.6%	69.2%	94.7%	33.3%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 25 periods

	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
ROE	17.4%	17.4%	18.0%	15.9%	21.8%	23.5%	24.4%	20.4%	21.4%	19.7%	21.1%	20.0%	21.0%	20.2%	21.1%	19.7%	20.6%	19.4%	20.3%	18.8%	19.8%	18.6%	19.4%	17.9%	18.6%
ROCE	20.9%	21.9%	23.0%	20.5%	27.9%	29.4%	30.9%	26.0%	27.1%	24.6%	25.4%	24.0%	25.2%	24.6%	26.2%	24.4%	25.6%	24.2%	25.4%	23.8%	24.8%	23.4%	24.3%	22.4%	23.5%
Net margin	24.6%	23.1%	22.5%	22.9%	23.1%	24.1%	23.9%	23.9%	24.1%	24.3%	25.1%	25.7%	26.0%	26.7%	26.8%	27.0%	27.2%	27.0%	27.3%	27.6%	28.3%	28.8%	29.3%	29.3%	29.1%
EBITDA margin	28.7%	29.4%	29.7%	31.3%	31.2%	31.4%	31.5%	31.1%	30.7%	29.8%	29.4%	30.1%	30.7%	31.7%	32.5%	32.6%	32.8%	33.0%	33.1%	33.4%	33.8%	34.2%	34.7%	34.8%	34.8%
Debt / equity	0.04	0.04	0.04	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest coverage	643.81	299.62	240.99	226.40	248.79	327.31	395.55	552.19	820.18	987.00	668.48	572.29	469.53	485.44	631.59	724.45	1076.75	1060.19	1096.29	1110.48	956.20	1072.41	1111.01	913.23	959.59
Asset turnover	0.60	0.63	0.68	0.60	0.82	0.85	0.89	0.73	0.76	0.68	0.70	0.67	0.69	0.65	0.68	0.63	0.65	0.63	0.65	0.60	0.62	0.58	0.60	0.54	0.57

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 18 periods

	JUN '14‡	MAR '15‡	JUN '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26
Share capital	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15
Other equity / reserves	47	78	78	113	210	349	618	933	1,171	1,469	1,671	1,865	2,058	2,301	2,527	2,835	3,144	3,571
Total equity	62	93	93	128	225	364	633	948	1,186	1,484	1,686	1,880	2,074	2,316	2,543	2,850	3,159	3,586
Borrowings	2	1	1	1	0	0	1	36	17	0	0	3	2	1	1	1	0	1
Current liabilities	108	125	125	125	—	—	—	—	—	—	294	268	294	331	329	306	285	386
Non-current liabilities	10	10	10	14	—	—	—	—	—	—	13	16	16	20	20	16	20	29
Total assets	180	229	229	267	358	500	743	1,126	1,364	1,736	2,021	2,191	2,413	2,697	2,924	3,209	3,504	4,045
Property, plant & equipment	102	113	113	144	150	167	225	266	297	277	273	267	269	439	452	530	523	547
Capital work-in-progress	25	30	30	0	3	15	10	20	14	15	55	220	275	117	153	139	177	209
Investments	0	0	0	0	17	47	70	61	11	89	142	230	246	376	514	590	636	859
Inventories	10	14	14	19	22	28	37	238	179	227	296	288	337	363	327	336	329	429
Receivables	0	6	6	8	33	126	160	229	279	320	371	394	459	543	618	632	694	826
Cash & equivalents	27	45	45	68	43	62	49	50	232	151	374	178	138	139	177	199	108	94

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 14 periods

	Jun '14‡	FY15‡	Jun '15‡	FY16‡	FY17‡	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	60	50	50	42	68	66	83	45	269	337	272	311	432	523
Cash from investing	-44	-23	-23	-6	-36	-69	-100	-54	-29	-271	-218	-313	-335	-582
Cash from financing	-6	-9	-9	-14	-7	-12	90	80	-24	-41	-28	-38	-38	-46
Capex	—	—	—	—	—	—	—	—	—	91	194	146	192	248
Free cash flow	—	—	—	—	—	—	—	—	—	246	78	165	241	275
Dividends paid	4	7	7	14	6	11	15	33	3	23	30	34	38	46

Where the assets sit

Mar '26 · ₹ crore

Fixed assets (PPE)

₹547 cr14%

CWIP

₹209 cr5%

Investments

₹859 cr21%

Inventories

₹429 cr11%

Receivables

₹826 cr20%

Cash & equivalents

₹94 cr2%

Other assets

₹1,082 cr27%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Caplin Point Laboratories Ltd.	18,107	2,382.50	27.2	5.05	18.6%

StoxGud checklist: Bullish setup · 9/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-10.1%

6 months+27.6%

1 year+17.9%

3Y CAGR+29.7%

5Y CAGR+22.9%

10Y CAGR+20.1%

50-day avg₹2,554.81

200-day avg₹2,176.64

RSI (14)59

Compare Caplin Point Laboratories Ltd. with

Granules India vs Caplin Point Laboratories Onesource Specialty Pharma vs Caplin Point Laboratories Caplin Point Laboratories vs Syngene International Caplin Point Laboratories vs Cohance Lifesciences Caplin Point Laboratories vs Poly Medicure

FAQs

What is the share price of Caplin Point Laboratories Ltd.?

Caplin Point Laboratories Ltd. (CAPLIPOINT) closed at ₹2,382.50 on NSE on 06 Nov 2026.

What is the market cap of Caplin Point Laboratories Ltd.?

₹18,107 crore at the latest close.

What is the P/E ratio of Caplin Point Laboratories Ltd.?

27.2, on trailing-twelve-month earnings from its filings.

How fast is Caplin Point Laboratories Ltd. growing?

Caplin Point Laboratories Ltd.: revenue has compounded at 14.2% a year over three years; net profit at 19.4% a year. Latest-quarter revenue is up 19.6% year on year, profit up 15.8%.

How profitable is Caplin Point Laboratories Ltd.?

On a trailing-twelve-month basis return on equity is 18.6%, return on capital employed 23.5%, operating margin 34.8%, net margin 29.1%.

How much debt does Caplin Point Laboratories Ltd. have?

Caplin Point Laboratories Ltd. is debt-free: debt to equity is 0.00 with borrowings of ₹1 cr against cash of ₹94 cr (balance sheet of 2026-03-31). Operating profit covers interest 959.6 times.

Financials parsed from Caplin Point Laboratories Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Jun '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.